Medications That Increase Serum Potassium
The most clinically important medications that increase serum potassium are aldosterone antagonists (spironolactone, eplerenone), ACE inhibitors, ARBs, and potassium-sparing diuretics, with aldosterone antagonists posing the highest risk, particularly when combined with other RAASi agents. 1
Primary Offenders by Drug Class
Aldosterone Antagonists (Highest Risk)
- Spironolactone and eplerenone cause hyperkalemia by directly inhibiting potassium excretion in the distal nephron 1
- Hyperkalemia occurs in 2-5% in clinical trials but 24-36% in real-world practice 1
- Risk dramatically increases when serum creatinine >1.6 mg/dL or GFR <30 mL/min 1
- Do not initiate if baseline potassium >5.0 mEq/L 1
RAAS Inhibitors
ACE inhibitors (enalapril, lisinopril, captopril): Typically increase potassium by ~1 mEq/L 2
ARBs (candesartan, olmesartan, valsartan): Similar potassium elevation to ACE inhibitors 3, 4
- 37-40% of CKD stage 3 patients develop potassium >5.0 mEq/L 4
Angiotensin receptor-neprilysin inhibitors (sacubitril-valsartan): Comparable risk to ARBs 5
Potassium-Sparing Diuretics
- Amiloride, triamterene: Directly block sodium channels in collecting duct, reducing potassium excretion 6, 7
- Particularly dangerous when combined with ACE inhibitors or ARBs 2, 6
Additional Medications
NSAIDs: Impair renal potassium excretion by reducing renin release 2, 1, 7
Trimethoprim-sulfamethoxazole: Blocks epithelial sodium channels, mimicking amiloride 8, 9
- Avoid in patients on ACE inhibitors/ARBs with reduced kidney function 8
Beta-blockers: Cause transcellular potassium shift, typically modest increases 7, 10
- Metoprolol increased potassium from 4.11 to 4.27 mmol/L in acute MI patients 10
Heparin and derivatives: Suppress aldosterone synthesis 7
Calcineurin inhibitors (tacrolimus, cyclosporine): Impair renal potassium excretion 7
Pentamidine: Directly toxic to potassium-secreting cells 7
Direct renin inhibitors (aliskiren): Block RAAS upstream 7
Critical Drug Combinations to Avoid
Triple therapy with ACE inhibitor + ARB + aldosterone antagonist should be avoided unless under specialist supervision 11, 1
The combination of ACE inhibitor/ARB + MRA + trimethoprim poses extreme hyperkalemia risk 8, 9
Potassium supplements + any RAAS inhibitor requires discontinuation or dose reduction of supplements 1
Risk Factors That Amplify Drug-Induced Hyperkalemia
- Renal dysfunction: Risk increases progressively when creatinine >1.6 mg/dL 1
- Diabetes mellitus: Hyporeninemic hypoaldosteronism 2
- Advanced age: Reduced renal reserve 12
- CKD stage 4-5: MRAs have highest impact (+0.86 mEq/L) 12
- Dehydration or acute illness: Temporarily stop aldosterone antagonists 1
Monitoring Requirements
For aldosterone antagonists specifically:
- Check potassium at 3 days, 1 week, then monthly for 3 months 1
- Subsequently every 3 months 1
- Reinitiate monitoring cycle when ACE inhibitor/ARB dose increased 1
For ACE inhibitors/ARBs:
- Check within 1 week of initiation or dose escalation 9
- Up to 30% creatinine increase is acceptable if stabilizes 11
Management Thresholds
Potassium 5.5-6.0 mEq/L: Halve aldosterone antagonist dose (e.g., 25 mg every other day) 3, 1
Potassium >6.0 mEq/L: Stop aldosterone antagonist immediately 3, 1
Potassium >6.5 mEq/L: Discontinue or reduce all RAAS inhibitors 9
Common Pitfalls
The most dangerous error is combining multiple potassium-raising agents without adequate monitoring, particularly in patients with unrecognized renal dysfunction 1, 12. Real-world hyperkalemia rates are 5-10 times higher than clinical trials because of less stringent patient selection and monitoring 1.
Do not assume beta-blockers are benign—while their effect is modest, they contribute to hyperkalemia in polypharmacy settings 7, 10.
Clinicians frequently fail to adjust for low muscle mass in elderly patients, where serum creatinine underestimates renal dysfunction; always calculate GFR 1.
Counsel patients to avoid high-potassium foods and stop aldosterone antagonists during diarrheal illness 1.